Attention-deficit hyperactivity disorder (ADHD) is a prevalent and highly heritable disorder of childhood with negative lifetime outcomes. Although candidate gene and genome-wide association studies have identified promising common variant signals, these explain only a fraction of the heritability of ADHD. The observation that rare structural variants confer substantial risk to psychiatric disorders suggests that rare variants might explain a portion of the missing heritability for ADHD. Here we believe we performed the first large-scale next-generation targeted sequencing study of ADHD in 152 child and adolescent cases and 188 controls across an a priori set of 117 genes. A multi-marker gene-level analysis of rare ( o1% frequency) single-nucleotide variants (SNVs) revealed that the gene encoding brain-derived neurotrophic factor (BDNF) was associated with ADHD at Bonferroni corrected levels. Sanger sequencing confirmed the existence of all novel rare BDNF variants. Our results implicate BDNF as a genetic risk factor for ADHD, potentially by virtue of its critical role in neurodevelopment and synaptic plasticity.
INTRODUCTION
Attention-deficit hyperactivity disorder (ADHD) is a highly heritable psychiatric condition with a worldwide prevalence in childhood and adolescence of~5.3%. 1 ADHD is characterized by a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with social, academic or occupational functioning (DSM V 2 ). These symptoms are chronic, persist into adulthood in approximately half of affected individuals and are associated with impaired family and peer relationships, increased risk for drug abuse and criminality and significantly increased mortality rates. 3 Large twin studies indicate that the key aetiological factors of ADHD are genetic, with heritability estimated at 75-90%. 4 Although recent polygenic risk analyses suggest that a substantial portion of this heritability can be explained by the cumulative effects of common genetic variants,~70% of the heritability of ADHD remains unexplained. 5 As a growing body of evidence now supports the involvement of rare variants in the aetiology of common diseases such as ADHD, it is possible that much of the so-called 'missing heritability' of ADHD will be accounted for by rare variants. In line with this hypothesis, rare structural DNA abnormalities known as copy-number variations (CNVs) have been implicated in the aetiology of several psychiatric disorders including autism, schizophrenia and ADHD. For example, a number of CNV studies have demonstrated that children with ADHD have a significant excess of large CNVs. 6, 7 Yet while the CNV work represents a promising start to investigating the role of rare variants in ADHD, the majority of implicated CNVs are not highly penetrant and have limited overlap between studies (see Hawi 2015 for a review 8 ).
Aside from CNVs, the most prevalent rare variants in the genome are single-nucleotide variants (SNVs) and insertions/ deletions (InDels). Promising results for analyses focusing on SNVs and InDels are just beginning to emerge for psychiatric phenotypes. For example, Kenny et al. 9 recently employed nextgeneration sequencing and observed an increased overall burden of SNVs and InDels in both schizophrenia and autism spectrum disorder. Hence these two classes of rare variation represent a sensible starting point for investigations of the role of rare variants in ADHD. To define the search space for potential rare variant associations with ADHD, we curated the published molecular genetic literature of ADHD to yield a set of genes for targeted (exon plus partial untranslated regions (UTR)) sequencing that had a priori evidence of association. We included genes showing evidence of association with ADHD from candidate gene, genome-wide association (GWA) and CNV studies. We then conducted burden analyses for SNVs and InDels at the level of each gene. To the best of our knowledge, these analyses indicated for the first time that rare variation in the brain-derived neurotrophic factor gene (BDNF) is associated with ADHD.
MATERIALS AND METHODS

Gene selection
Recent research indicates that ADHD is associated with a significant overlap of biological pathways enriched for both common variants and rare CNVs, 8, 10, 11 suggesting that perturbation in these pathways is critical for conferring risk to ADHD. Thus we restricted the search space for rare SNVs and InDels that may be associated with ADHD by focusing on those genes implicated in previous research. We conducted a comprehensive literature review in order to identify genes showing evidence of association with ADHD under candidate gene and GWA designs. Specifically, genes were selected from candidate gene studies if the original report of association with ADHD was replicated via independent GWAS evidence, meta-analysis or at least one independent candidate gene study (both sources significant at P o0.05). Two additional candidate genes (PER2, CSNK1E) were included because an association with ADHD at P o0.05 was supported by very strong functional evidence. We also included genes from childhood ADHD GWA studies [12] [13] [14] [15] where variants were associated with ADHD at Po 1 × 10 − 4 and the copy-number variant GWAS (CNV-GWAS) of Williams et al. 6 when two or more ADHD cases (but not controls) showed CNV's that overlapped a given gene (we note that the latter genes were selected just prior to the Williams et al., 7 multisite CNV study). The application of these inclusion criteria yielded 117 genes for targeted sequencing (31, 48, 38 genes; candidate gene, SNP-GWAS, CNV-GWAS, respectively; see Supplementary Table 1 ).
Participants
Our sample comprised 152 ADHD cases and 188 controls from among subjects recruited in the Republic of Ireland. 11, 16 Recruitment and ascertainment of ADHD cases was approved by the Eastern Regional Health Authority research ethics committee and written informed consent was obtained from parents. The control subjects were ascertained with written informed consent from the Irish Biobank. Detailed demographic, epidemiological and clinical descriptions of these samples have been presented previously in separate GWAS. [16] [17] [18] Briefly, the ADHD sample was composed of clinically diagnosed ADHD children and adolescents recruited from child guidance clinics and ADHD support groups. Exclusion criteria included: epilepsy, fragile X syndrome, foetal alcohol syndrome, pervasive developmental disorder, Tourette syndrome, psychosis and IQo 70. To confirm DSM-IV and/or ICD-10 diagnoses of ADHD, one or both parents of each child were interviewed using the Child and Adolescent Psychiatric Assessment (CAPA).
19 DSM-IV 20 and ICD-10 21 criteria for symptom pervasiveness were confirmed by obtaining information about ADHD symptoms at school via a semi-structured teacher telephone interview. The sample of ADHD cases had a mean age at collection of 10.10 years (s.d. = 3.49). The control sample was composed of blood donors to the Irish Blood Transfusion Service that had given informed consent to the Trinity Biobank. 16 As individuals regularly taking prescription medication (including for psychiatric and other disorders) are excluded from blood donation in Ireland and, as the lifetime prevalence of ADHD is relatively low, there is no obvious reason to expect that individuals with ADHD would be overrepresented in this control sample. The control sample had a mean age at collection of 44.50 years (s.d. = 12.49).
DNA isolation, targeted sequencing and quality control
Identical DNA collection and isolation protocols were used for the case and control samples. DNA was isolated from blood using standard procedures. The physical condition of the DNA was comparable for both samples and the purity measured as optical density at 260/280 ranged between 1.7 and 1.9 indicating good DNA quality. An Agilent SureSelect (Agilent Technologies, Santa Clara, CA, USA) custom capture target was designed that contained capture baits for the coding and UTR regions of genes of interest, including 117 genes specifically chosen for this study. In order to increase the likelihood that we could target each region with at least two SureSelect 120-mer probes, any target region under 120 bases was artificially inflated to 121 bases. This final co-ordinate list was uploaded to Agilent Technology's eArray design website to design the SureSelect Target Enrichment array. Library preparation of each sample involved a two-step process. In the first step, the DNA was prepared as an Illumina sequencing library, and in the second step, the sequencing library was enriched for the desired target using the Agilent SureSelect enrichment protocol (as described by Kenny et al.; 9 see Supplementary Information). Nextgeneration sequencing was then conducted on an Illumina HiSeq2000 at the Queensland Brain Institute, Brisbane, Australia. Image processing and sequence extraction were performed using the standard Illumina Genome Analyzer software and the quality of raw reads was evaluated by FastQC (v0.10.1) software. A custom PERL script was then used to de-multiplex the samples and generate the short reads for each sample in 'fastq' format.
Approximately 20 Gb of sequence data was generated for a total sample of 340 individuals. Sequence alignment and calling of SNVs and InDels involved mapping with BWA v0.6.2 22 and SNV and InDel identification with GATK v 2.2-8. 23, 24 To ensure high-quality variant calling by GATK, we filtered variants by following the GATK Best Practice Variant Detection protocol. Briefly, we aligned the paired-end reads to the human reference genome (B37) with BWA followed by marking of duplicates with Picard software (http://picard.sourceforge.net). We then applied the GATK genotyping pipeline that includes 'base quality score recalibration', 'InDel realignment', and 'multi-sample SNP and InDel calling'. SNP and InDel discovery and genotyping were performed across all 340 samples simultaneously (multi-sample calling) by using GATK Unifiedgenotyper. The GATK Best Practice Variant Detection protocol excluded SNVs with: a quality by depth score (QD) o2.0, a mapping quality score (MQ) o 40.0, a mapping quality rank sum score (MQranksum) o12.5, a Fisher strand score (FS) 460.0, a haplotype score 413.0 or a read position rank-sum test score (ReadPosRankSum) less than − 8.0. These filters ensured that: (1) there was a high variant call confidence based on unfiltered depth of non-reference samples (QD); (2) the mapping quality of the reads across all samples was high (MQ, MQranksum); (3) there was low strand bias for detection of variants (FS)-as strand bias is indicative of false positive calls; (4) the site was consistent with two, and only two segregating haplotypes (HaplotypeScore)-as high scores are indicative of regions with bad alignments, often leading to artifactual SNP calls; and (5) positions of any detected variants were not biased to the end of the reads (ReadPosRankSum)-as alternate allele reads that only occur near the end of the read are indicative of error. The GATK Best Practice protocol was also applied to InDels to remove variant calls with: QD o2.0, ReadPosRankSum less than − 8, FS 4200 and inbreeding coefficients less than − 0.8 (the former three filters were employed for aforementioned reasons and the inbreeding coefficient filter accounted for inbreeding among samples).
A further genotyping quality control was then conducted in SNP and Variation Suite v8.3 (SVS 8.3; Golden Helix, Bozeman, MT, USA). For SNV data we removed variants that: (1) were monoallelic or had more than one alternative allele; (2) had an average read depth (across samples) o10x, (3) had a genotyping fail rate across all samples 410%. We also applied a filter to remove subjects with a genotyping fail rate across all variants 410%, however the high quality of the data entailed that no subjects were removed under this criterion.
Relatedness and population stratification analyses
Analyses for relatedness and population stratification were also performed using SVS 8.3. An analysis for relatedness among individuals in the sequencing sample was conducted with the data from the corresponding subset of GWAS participants (n = 340). The genotyping for the ADHD-GWAS analysis had previously been performed on an Illumina Human 660 W-Quad BeadChip (San Diego, CA, USA), while the control samples had been genotyped using the Affymetrix 6.0 platform (Santa Clara, CA, USA). The SNPs that were common to both case and control GWAS data sets (139 100 SNPs) provided ample data for relatedness analyses. The combined data set was LD pruned (window size: 100, window increment: 5, LD r 2 threshold = 0.5, LD computation: CHM) to leave 101 163 SNPs for identity by state (IBS) estimation. IBS values of 1 and 0.309 were obtained for a control pair and a case/control pair, respectively. These IBS values were consistent with: the existence of a duplicate sample in the Control group (IBS = 1) and a second-degree relative case/control pairing (IBS = 0.309). Consequently three individuals on which sequencing had been conducted were excluded, leaving a sample of 337 subjects.
In order to test for population structure, the combined case/control common SNV (minor allele frequency (MAF) 45%) data arising from our next-generation sequencing (N = 337) was then submitted to a principal components analysis (with LD pruning conducted as above). In line with previous GWAS investigations that were conducted separately in the case and control samples, 11, 16 no ethnic sub-groups were observed. Thus a final sample of 337 participants (152 cases, 185 controls) remained for further Rare BDNF gene variants increase risk for ADHD Z Hawi et al analyses. The mean coverage in this final sample was 4100 times for both ADHD cases and controls (102.4 × , 113.2 × , respectively; ⩾ 40 × mean coverage achieved across 98% of all samples) and we observed 499% matching between common variant calls (MAF 40.05) in our sequenced regions and corresponding GWAS data. 11, 16 This level of coverage was associated with high-quality data that was comparable across cases and controls; phred-scaled confidence values for genotype call were above 20 in 97.65% of cases and 97.16% of controls and above 99 in 85.04% of cases and 84.73% of controls.
We note that as our samples have contributed to previous (GWA) common variant 11 and CNV 7 studies we do not include such analyses in this paper.
Rare variant annotation and analysis
The final rare variant data set was constructed and analysed in SVS 8.3. Sequencing variants were classified as rare if they had a MAF of o 0.01 in the combined case-control sample. 9, 25, 26 Our sample size of 337 subjects has power in excess of 80% to detect rare variants with a minor allele frequency ⩾ 0.0024. Filtering for rare variants resulted in a set of 2702 rare SNV's which were then functionally annotated with the Combined Annotation Dependent Depletion (CADD) tool to provide both PHREDscaled CADD scores (C-score) and information on variant consequences. 27 As C-scores 410 are indicative of a high likelihood of pathogenicity 27 (predicted to be in the top 10% of deleterious substitutions), we filtered for rare variants using this criterion in order to construct a set of putatively functional variants. This filtering process resulted in a set of 1288 rare putatively functional SNVs (hereafter referred to as rare functional SNVs). Gene-level analyses were then conducted across our rare functional SNV set using the adaptive permutation version of the kernel-based adaptive cluster method. 28 For each gene we conducted 100 000 iterations and used a Bonferroni-corrected threshold (0.05/number of genes) to determine significance.
A complementary analysis tested for the impact of rare loss-of-function (LoF) variants (both SNVs and InDels); that is those variants that are predicted to severely disrupt protein-coding sequences. Following recent studies, 9, 29 we defined the following variant types as LoF if they were located in a protein-coding transcript: nonsense SNVs that introduce stop codons; SNVs and InDels that disrupt splice sites; and InDels that disrupt a transcript's open reading frame. With these criteria, we observed a total of 10 unique LoF variants distributed over 10 genes (four stop-gain SNVs, five splice-site disruption SNVs, one frameshift InDel). For each of these genes, we conducted Fisher's exact tests for association with case-control status and corrected for multiple comparisons with a Bonferroni correction (see Supplementary Table 4) .
RESULTS
Gene-level analyses were conducted across our rare functional SNV set using the adaptive permutation version of the kernelbased adaptive cluster method. 28 As Table 1 shows, this analysis revealed a significant association between ADHD and the gene encoding BDNF, with 20 ADHD cases versus 6 controls showing variation across 12 rare SNVs, (kernel-based adaptive cluster method stat = 8.594, P = 3.00 × 10 − 4 ; Figure 1 ). Each of these individuals contributed a single rare variant with the exception of one ADHD case that had a rare BDNF variant at two positions (positions: 27695869 and 27741140), indicating that this result was not driven by a high burden of rare variants in one or more cases. A further two genes (ITPR2, CLYBL) showed nominally significant associations (significant at uncorrected level, α = 0.05) Supplementary Table 3 . In order to demonstrate the stability of our BDNF result, we ran an alternative gene level analysis, the weighted sum test, 30 on our rare functional SNV set. Notably, this test also returned a significant result for BDNF at corrected levels, P = 2.85 × 10
We next sought to validate each of the 12 BDNF SNVs identified in the above analysis. Table 1 lists the chromosomal positions of each of the rare functional BDNF SNVs identified in our study. Sanger sequencing on the PCR product of these variants was conducted for every novel rare BDNF SNV. In every case Sanger sequencing confirmed the existence of the SNV confirming the fidelity of our next-generation sequencing data.
Bioinformatic analysis of the 12 BDNF variants was then performed. We used the Alamut splicing module (Interactive Biosoftware, Rouen, France) to predict alternative splicing for variants located at exon/ intron boundaries. Further, variants in proximity to the transcription start site were assessed for cis-regulatory transcriptional control using data from the Encyclopedia of DNA Elements (ENCODE) consortium 31 and the US National Institutes of Health (NIH) Roadmap Epigenomics Project. 32 Although one novel non-synonymous variant was identified in the pro-region of BDNF (position: 27695742), PolyPhen2 and SIFT both predicted the C-G substitution to be benign. Multiple variants were predicted to affect both splicing (position: 27695893) and transcriptional control (positions: 27722647; 27741048; 27741140; 27743438; 27743449; 27743481 and 27743556) of BDNF (Supplementary Table 2 ).
Further analyses involved testing for the impact of rare LoF variants (SNVs and InDELs). Of the 10 genes that held LoF variants, 9 had insufficient variation to achieve the asymptotic properties of the Fisher's test statistic (see Keizun et al. 33 ). That is, for the majority of genes, the rarity of the LoF variants in combination with the sample size entailed that a P-value o 0.05 was not achievable (regardless of how the variants were distributed between cases and controls). The one gene that was sufficiently powered (ZNF544) for a loss of function gene-level analysis, did not show a significant case/control difference (Supplementary Table 4 ).
DISCUSSION
It is widely appreciated that genetic risk for psychiatric disorders is conferred by multiple gene variants acting across a range of allele frequencies. Although the bulk of previous molecular genetic work in ADHD has focused on the contribution of relatively common gene variants, here we examined the contribution of rare genetic variation, assayed using next generation sequencing. We performed the first large-scale targeted (exon plus UTR) capture across 117 genes in 152 child and adolescent cases with ADHD compared with 188 controls. Our results show that ADHD is associated with an enrichment of putatively functional, rare SNVs mapped to the gene encoding BDNF.
BDNF is critically important for neural development, differentiation and plasticity in both the developing and adult brain. 34, 35 The relevance of BDNF to ADHD is underscored by several observations. First, BDNF conditional knockout mice display a phenotype Abbreviations: BDNF, brain-derived neurotrophic factor; MAF, minor allele frequency; SNV, single-nucleotide variant. Position: SNV positions on chromosome 11 (under build GRCh37.p13). Note: each individual contributed a single rare variant with the exception of one ADHD case that had a BDNF rare variant at two positions (positions: 27695869 and 27741140).
Rare BDNF gene variants increase risk for ADHD Z Hawi et al that includes impulsivity, a core feature of ADHD. 36, 37 Second, BDNF is an essential neurotrophic factor for both dopaminergic and serotonergic neurons, disruption of which has been implicated in the pathophysiology of ADHD. [38] [39] [40] Third, animal studies demonstrate that psychostimulants such as methylphenidate that are used in the treatment of ADHD, modulate BDNF expression. 41, 42 A common exonic Val66Met substitution within the pro-region of BDNF has been widely implicated as contributing to a diverse range of cognitive functions and psychiatric disorders, including ADHD. 35, 43 The Val66Met polymorphism is widely believed to disrupt activity-dependent release of BDNF with consequences for physiological processes modulated by BDNF such as neurotransmitter release. Although we identified one non-synonymous variant located within the pro-region of BDNF, its rarity entails low LD between this variant and the Val66Met SNP. Further, bioinformatics suggested a low probability of pathogenicity. Our next-generation sequencing nevertheless identified other variants with high likelihoods of pathogenicity including splice variants that could result in aberrant transcript processing of BDNF, and multiple variants located close to the 5′ UTR which are likely to result in changes to cis-regulatory transcriptional control of BDNF. The high likelihood of pathogenicity associated with the identified BDNF variants, in combination with the observation that all the associated BDNF transcripts are expressed in brain regions relevant to ADHD 44 such as the frontal cortex and cerebellum, highlights the potential relevance of our findings to the aetiology of ADHD.
Our novel application of next-generation sequencing to ADHD raises several methodological issues that warrant comment. First, we conducted targeted exon plus partial UTR capture across 117 genes rather than an exome-wide approach. This approach was justified given emerging evidence of overlap between common and rare variant signals in complex traits and the high costs of whole-exome compared with targeted sequencing approaches at the time of commencement of this study. Our decision to restrict our analysis to variants with a high likelihood of pathogenicity based on CADD scores and the subsequent confirmation of all BDNF variants by Sanger sequencing, suggests that our study has likely identified a meaningful rare variant signal. Nevertheless, we recognize the inherent bias in our targeted sequencing approach and the requirement for replication in independent whole-exome sequencing studies. Second, although we identified an SNV association at Bonferroni-corrected levels, our study was underpowered for a gene-level analysis of LoF variants. Our finding that only one gene carried sufficient LoF variants for a meaningful statistical test is consistent with past studies, 9 including a recent survey of LoF variants that observed an average of only 100 LoF variants across an individual's entire genome. 29 Together these results show that establishing an aetiological role for LoF variants at the gene level for complex traits will require extremely large samples. Third, our samples of cases and controls were not tightly matched on demographic variables such as age, rendering this a limitation of our study. Although the use of age-matched controls should be an aspiration for future sequencing work, it is worth noting that the use of opportunistic control cohorts is not uncommon in psychiatric genetic studies of both common and rare variants.
In summary, this study provides preliminary evidence that rare DNA variation in BDNF, putatively via its varying effects on neurodevelopmental or plastic processes, confers risk to ADHD. Although our finding requires replication, it may encourage functional genomic exploration of the molecular risk mechanism. Figure 1 . Plot of -log10 P values for each gene showing that the BDNF gene is significant at Bonferroni-corrected significance levels. The red horizontal line represents the threshold for Bonferroni-corrected significance, the grey horizontal line represents the threshold for nominal significance (P o0.05).
